COA_Karl said:

The liver data is among the strongest non-weight findings in the class.

This is where I part company with the consensus forming above. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

anders_CPH said:

This treats a plausible mechanism as a demonstrated one.

There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

That is the short version; the long version is somebody else's post.

A narrower follow-up, since the general answer is now clear:

Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?

OP back with an update, since a thread like this is useless without one.

Reporting back with a partial result, because a partial result is still better than silence. Two of the three things suggested helped; I cannot separate them and I am not going to pretend otherwise.